Journal rankings · indicator year 2002
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2002
Oncology journal rankings 2002
96 ranked journals · Subfield in Medicine
Oncology has 96 ranked journals in 2002. The median OJR rose 0.08 on 2001 to 0.70, below the world average of 1.00; Q1 starts at OJR 1.20. The top three are CA A Cancer Journal for Clinicians, Nature Medicine, and Journal of Clinical Oncology.
Ranks and citation indicators: 2002. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 1999–2001, the window the 2002 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery358
- Pulmonary and Respiratory Medicine133
- Public Health, Environmental and Occupational Health125
- Cardiology and Cardiovascular Medicine124
- Oncology96
- Epidemiology87
- Infectious Diseases78
- Psychiatry and Mental health74
- Radiology, Nuclear Medicine and Imaging65
- Neurology64
- Physiology62
- Endocrinology, Diabetes and Metabolism57
Show all 42 subfields
- Dermatology47
- Hematology47
- Orthopedics and Sports Medicine47
- Pediatrics, Perinatology and Child Health46
- Ophthalmology42
- Obstetrics and Gynecology36
- Nephrology26
- Pharmacology26
- Rheumatology25
- Emergency Medicine23
- Reproductive Medicine22
- Otorhinolaryngology18
- Complementary and alternative medicine16
- Pathology and Forensic Medicine15
- Rehabilitation15
- Geriatrics and Gerontology13
- Immunology and Allergy13
- Critical Care and Intensive Care Medicine11
- Anesthesiology and Pain Medicine9
- Genetics8
- Hepatology7
- Gastroenterology6
- Urology5
- Internal Medicine3
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
96 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2001. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 1999–2001, the window the 2002 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 1999–2001 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2000 to 2002. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 12.04Q1 | 28.24 4.09 up from 2001 | 69 | 100% | $4,330 | ||
2Nature MedicineNature Portfolio · United States | 6.00Q1 | 13.69 1.03 up from 2001 | 1,179 | 12% | $12,690 | ||
3Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 4.58Q1 | 9.65 1.17 up from 2001 | 1,686 | 2% | — | ||
4JNCI Journal of the National Cancer InstituteOxford University Press · United States | 4.14Q1 | 9.45 0.49 up from 2001 | 838 | 23% | $5,436 | ||
5Seminars in Cancer BiologyElsevier BV · United States | 2.61Q1 | 5.79 0.72 up from 2001 | 134 | 3% | $6,060 | ||
6Clinical Pharmacology & TherapeuticsWiley · United States | 2.34Q1 | 3.62 0.22 down from 2001 | 415 | 3% | $4,410 | ||
7JNCI MonographsOxford University Press · United Kingdom | 1.93Q1 | 3.39 1.16 up from 2001 | 111 | — | — | ||
8Seminars in OncologyElsevier BV · United States | 1.87Q1 | 3.49 3.49 up from 2001 | 221 | 0% | $3,550 | ||
9CancerWiley · United States | 1.70Q1 | 3.54 0.46 up from 2001 | 2,780 | 57% | $4,790 | ||
10Current Opinion in OncologyLippincott Williams & Wilkins · United Kingdom | 1.68Q1 | 4.32 1.41 up from 2001 | 250 | 0% | — | ||
11Psycho-OncologyWiley · United Kingdom | 1.67Q1 | 2.09 0.32 down from 2001 | 161 | 8% | $4,940 | ||
12Cancer Causes & ControlSpringer Science+Business Media · Netherlands | 1.59Q1 | 3.09 0.29 up from 2001 | 301 | 10% | $3,890 | ||
13Cancer Treatment ReviewsElsevier BV · United Kingdom | 1.53Q1 | 3.82 0.44 up from 2001 | 91 | 0% | $4,910 | ||
14Investigational New DrugsSpringer Science+Business Media · Netherlands | 1.52Q1 | 2.97 0.35 down from 2001 | 116 | 5% | $4,690 | ||
15The OncologistOAAlphaMed Press · United Kingdom | 1.51Q1 | 3.24 1.20 up from 2001 | 247 | 63% | $3,852 | ||
15European Journal of CancerElsevier BV · United Kingdom | 1.51Q1 | 3.09 0.18 up from 2001 | 1,097 | 1% | $4,270 | ||
17British Journal of CancerSpringer Nature · United Kingdom | 1.46Q1 | 3.21 0.28 down from 2001 | 2,170 | 98% | $5,190 | ||
18JBIC Journal of Biological Inorganic ChemistrySpringer Science+Business Media · Germany | 1.44Q1 | 2.70 0.17 up from 2001 | 272 | 14% | $3,990 | ||
19Journal of Mammary Gland Biology and NeoplasiaSpringer Science+Business Media · United States | 1.37Q1 | 2.91 0.40 down from 2001 | 112 | 11% | $4,090 | ||
20Annals of OncologyElsevier BV · Netherlands | 1.29Q1 | 2.76 0.17 up from 2001 | 1,135 | 98% | $5,080 | ||
21International Journal of CancerWiley · United States | 1.25Q1 | 3.11 0.15 up from 2001 | 2,884 | 60% | $5,030 | ||
22Hematology/Oncology Clinics of North AmericaElsevier BV · United States | 1.24Q1 | 2.50 0.28 up from 2001 | 213 | 0% | $3,950 | ||
23Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.22Q1 | 3.19 1.27 up from 2001 | 504 | 2% | — | ||
24Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.20Q1 | 2.79 0.53 up from 2001 | 220 | 3% | $4,190 | ||
25OncologyKarger Publishers · Switzerland | 1.17Q2 | 2.63 0.69 up from 2001 | 342 | 12% | — | ||
26Diseases of the Colon & RectumLippincott Williams & Wilkins · United States | 1.08Q2 | 2.20 0.40 up from 2001 | 1,029 | 1% | — | ||
27International Journal of Clinical Pharmacology and TherapeuticsDustri-Verlag · Germany | 1.04Q2 | 1.73 0.21 up from 2001 | 147 | 1% | — | ||
28Journal of Inorganic BiochemistryElsevier BV · United States | 0.98Q2 | 2.06 0.57 up from 2001 | 516 | 8% | $4,220 | ||
29Cancer Chemotherapy and PharmacologySpringer Science+Business Media · Germany | 0.98Q2 | 2.35 0.28 up from 2001 | 296 | 1% | $4,390 | ||
30Cancer NursingLippincott Williams & Wilkins · United States | 0.96Q2 | 1.45 0.26 up from 2001 | 187 | 1% | — | ||
31Journal of Clinical Pharmacy and TherapeuticsWiley · United Kingdom | 0.96Q2 | 1.46 0.11 up from 2001 | 178 | 49% | $2,700 | ||
32Journal of Clinical PathologyBMJ · United Kingdom | 0.95Q2 | 2.20 0.45 up from 2001 | 683 | 94% | — | ||
33Supportive Care in CancerSpringer Science+Business Media · Germany | 0.94Q2 | 1.53 0.07 down from 2001 | 214 | 6% | $4,690 | ||
34The Lancet OncologyElsevier BV · United Kingdom | 0.92Q2 | 1.67 1.20 up from 2001 | 194 | 1% | $7,280 | ||
35Cancer InvestigationTaylor & Francis · United Kingdom | 0.88Q2 | 1.85 0.40 up from 2001 | 284 | 1% | — | ||
36Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 0.86Q2 | 2.87 0.77 up from 2001 | 203 | 100% | $4,590 | ||
37Acta OncologicaOATaylor & Francis · United Kingdom | 0.83Q2 | 1.83 0.52 up from 2001 | 448 | 100% | — | ||
38Inorganica Chimica ActaElsevier BV · Netherlands | 0.83Q2 | 1.49 0.33 up from 2001 | 1,471 | 4% | $3,830 | ||
39Journal of Cancer Research and Clinical OncologyOASpringer Science+Business Media · Germany | 0.82Q2 | 1.95 0.06 down from 2001 | 227 | 100% | $4,390 | ||
40Surgical OncologyElsevier BV · United Kingdom | 0.80Q2 | 1.51 0.77 up from 2001 | 55 | 2% | $3,890 | ||
41MicrocirculationWiley · United States | 0.79Q2 | 1.31 1.01 down from 2001 | 187 | 4% | $3,920 | ||
42Journal of Surgical OncologyWiley · United States | 0.78Q2 | 1.53 0.25 up from 2001 | 472 | 6% | $4,570 | ||
43International Journal of Colorectal DiseaseSpringer Science+Business Media · Germany | 0.77Q2 | 1.34 0.22 down from 2001 | 205 | 7% | $3,790 | ||
44Current Problems in CancerElsevier BV · United States | 0.76Q2 | 0.73 0.79 down from 2001 | 31 | 0% | $3,740 | ||
45Clinical & Experimental MetastasisSpringer Science+Business Media · Netherlands | 0.75Q2 | 1.80 0.32 up from 2001 | 188 | 5% | $5,090 | ||
46Journal of Medical ScreeningSAGE Publishing · United Kingdom | 0.73Q2 | 1.65 0.13 up from 2001 | 106 | 23% | $4,150 | ||
47Cancer Detection and PreventionElsevier BV · Netherlands | 0.72Q2 | 0.00 1.55 down from 2001 | 66 | 0% | — | ||
48Journal of ImmunotherapyLippincott Williams & Wilkins · United States | 0.70Q2 | 2.92 1.35 up from 2001 | 271 | 11% | — | ||
49European Journal of Cancer PreventionLippincott Williams & Wilkins · United States | 0.70Q3 | 1.49 0.19 up from 2001 | 285 | 0% | — | ||
50Archives of Pathology & Laboratory MedicineOAAmerican Medical Association · United States | 0.68Q3 | 1.32 0.09 up from 2001 | 988 | 1% | — |
Subfields of Medicine, with Oncology highlighted.
- Surgery358
- Pulmonary and Respiratory Medicine133
- Public Health, Environmental and Occupational Health125
- Cardiology and Cardiovascular Medicine124
- Oncology96
- Epidemiology87
- Infectious Diseases78
- Psychiatry and Mental health74
- Radiology, Nuclear Medicine and Imaging65
- Neurology64
- Physiology62
- Endocrinology, Diabetes and Metabolism57
- Dermatology47
- Hematology47
- Orthopedics and Sports Medicine47
- Pediatrics, Perinatology and Child Health46
- Ophthalmology42
- Obstetrics and Gynecology36
- Nephrology26
- Pharmacology26
- Rheumatology25
- Emergency Medicine23
- Reproductive Medicine22
- Otorhinolaryngology18
- Complementary and alternative medicine16
- Pathology and Forensic Medicine15
- Rehabilitation15
- Geriatrics and Gerontology13
- Immunology and Allergy13
- Critical Care and Intensive Care Medicine11
- Anesthesiology and Pain Medicine9
- Genetics8
- Hepatology7
- Gastroenterology6
- Urology5
- Internal Medicine3
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
Journals
Citations made in 2002. Corpus-wide, 69.2% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
29 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 1999–2001, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2002. Publication window: 1999–2001. How these summaries are calculated
- Ranked journals
- 96
- Window papers (baseline)
- 44,340 Change unavailable from indicator year 1999
- Median OJR
- 0.70 Change unavailable from indicator year 1999
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 1999–2001 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.